Webinar: How to get Speed and Depth in your Host Cell Protein Analysis

Webinar Overview On-Demand Webinar, Recorded October 31st, 2018  HCPs are contaminants considered as Critical Quality Attributes in biotherapeutic drug preparations, and so must be monitored due to stability, efficacy and immunogenicity concerns. Immunospecific assays such as ELISA are currently the gold standard for QC applications, but there are long lead times for new assays based on process changes. Watch Webinar Now

What to Expect In this presentation, you will learn how PASEF (parallel accumulation and serial fragmentation), as implemented on the Bruker timsTOF PRO QTOF, can be applied to HCP analysis to achieve the goal of rapid and sensitive detection with quality data.

Speakers

Mike Greig  Mike Greig joined Bruker in 2018 as the Director of the US Pharma/Biopharma Business Unit for Bruker Daltonics. In the previous 20 years, he worked at Pfizer in Drug Discovery - most recently leading the Protein Dynamics Group, a core biological mass spectrometry research group focusing on Oncology. Previously, during his two decades at Pfizer, he directed labs performing everything from high throughput analysis of small molecule libraries using supercritical fluid-MS, protein NMR, native mass spectrometry, HDX-MS for structural biology, protein turnover, fragment-based drug design, to proteomics.